Exicure XCUR
NASDAQ XCUR
$1.16 +0.04 (+3.57%)
At close: Oct 2, 2026 · 4:00 PM EDT

Exicure (XCUR) Gains from Sales and Divestitures (2022 - 2026)

Updated

Exicure's Gains from Sales and Divestitures came in at $9,000 for Q2 2026, compared with -$60,000 a year earlier.

Analysis

Exicure (XCUR) Gains from Sales and Divestitures (2022 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Exicure reported Gains from Sales and Divestitures of -$32,000; for FY2025, it was -$90,000.

  • Going back by year, Gains from Sales and Divestitures was -$920,000 in FY2023.
  • The Q2 2026 figure represents the highest quarterly Gains from Sales and Divestitures since Q1 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Exicure 7.39 Mn 7.39 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 9,000.00
Mar 31, 2026 -37,000.00
Sep 30, 2025 -4,000.00
Jun 30, 2025 -60,000.00
Mar 31, 2025 -26,000.00
Sep 30, 2023 -876,000.00
Jun 30, 2023 -149,000.00
Mar 31, 2023 105,000.00
Dec 31, 2022 23,000.00
API Access

Exicure Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=XCUR&period=max&api_key=YOUR_API_KEY